Use of PAYCS in regulation of intestinal flora, metabolites, and brain neurotransmitters
US12128084B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 16, 2023 |
| Grant date | Oct 29, 2024 |
| Priority date | — |
| Expiry date | Feb 16, 2043 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure belongs to the technical field of health food, and in particular, relates to the use of PAYCS in the regulation of intestinal flora, metabolites, and brain neurotransmitters. PAYCS remedies scopolamine-induced memory impairment in mice through target oxidation, inflammatory stress and regulation of the intestinal microorganism-metabolite-brain neurotransmitter axis through PAYCS. PAYCS improves the memory pathway through the intestinal microorganism-metabolite-neurotransmitter axis. PAYCS can significantly reduce serum MDA and LDH levels and significantly increase liver SOD content. PAYCS-H inhibits the increase of liver TNF-α and IL-1β, while PAYCS-L can only reduce the content of TNF-α in the liver. Thus, PAYCS-L changes the ratio of Bacteroides/Firmicutes and increases the relative abundance of plants such as Cactaceae and Prevotellaceae, improving the neurotransmitters associated with the metabolism of tryptophan in the brain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.